CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion

Opinion
Video

Panelists discuss how they determine the optimal timing of temozolomide administration - concurrent or adjuvant - for WHO grade 3 astrocytomas lacking 1p/19q codeletion, drawing on evidence from the CATNON trial to inform their decision-making process.

  • How do you approach the use of concurrent versus adjuvant temozolomide in treating WHO grade 3 astrocytomas without 1p/19q codeletion?
    • CATNON trial
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Vinay K. Puduvalli, MD, is featured in this series.
3 experts in this video
3 experts in this video
Related Content